Does restoration of progenitor cell function rescue anthracycline cardiomyopathy?
Autologous cardiac progenitor cells may offer a potential therapeutic strategy for preventing or managing anthracycline-induced heart failure.
Our results raise the possibility that autologous CPCs can be obtained before antineoplastic drugs are given to cancer patients and subsequently administered to individuals who are particularly sensitive to the cardiotoxicity of these agents for prevention or management of heart failure.
Angelis et al. (Tue,) studied this question.